Technology | March 04, 2015

FDA Approves Rivaroxaban Starter Pack for Deep Vein Thrombosis and Pulmonary Embolism

Starter pack provides 30-day supply of Xarelto for initial treatment

Xarelto, rivaroxaban, Starter Pack, FDA, deep vein thrombosis, pulmonary embolis

March 4, 2015 — The U.S. Food and Drug Administration (FDA) has approved the Xarelto Starter Pack for deep vein thrombosis (DVT) and/or pulmonary embolism (PE) treatment. The starter pack was designed to help simplify the dosing for the initial 30-day treatment period when patients are at greatest risk of having another DVT or PE.

Xarelto (rivaroxaban) was a factor Xa inhibitor approved for DVT/PE treatment and reducing the risk of their recurrence in November 2012.

The Xarelto Starter Pack will help guide physicians and patients through the initial treatment process for DVT/PE.

Most patients diagnosed with DVT/PE receive their initial treatment in the hospital and are referred to outside healthcare providers for follow-up and ongoing treatment. The Xarelto Starter Pack helps reduce challenges faced by patients and providers by providing sufficient drug supply to be administered during the all-important 30-day period when patients are most vulnerable to another event. Also, it gives the patient time to follow up with their primary care physician after leaving the hospital for further evaluation and ongoing care.

For more information: www.janssenpharmaceuticalsinc.com

Related Content

Naveen Pereira, M.D., co-principal investigator of the TAILOR-PCI study, explaining the conclusions of the late-breaking trial data during the virtual ACC20 meeting. #ACC20 #ACC2020

Naveen Pereira, M.D., co-principal investigator of the TAILOR-PCI study, explaining the conclusions of the late-breaking trial data during the virtual ACC20 meeting. 

News | Antiplatelet and Anticoagulation Therapies | March 28, 2020
March 28, 2020 — The TAILOR-PCI trial that used genetic testing to guide which antiplatelet medication was given to p
The U.S. Food and Drug Administration (FDA) has approved two applications for the first generics of the anticoagulant Eliquis (apixaban).

The U.S. Food and Drug Administration (FDA) has approved two applications for the first generics of the anticoagulant Eliquis (apixaban).

Feature | Antiplatelet and Anticoagulation Therapies | December 27, 2019
December 27, 2019 — The U.S.
aspirin bottle
News | Antiplatelet and Anticoagulation Therapies | December 12, 2019
December 12, 2019 — Low-dose aspirin was not associated with a reduced risk of a fatal heart attack among African Ame
Videos | Antiplatelet and Anticoagulation Therapies | October 11, 2019
Ajay J. Kirtane, M.D., associate professor of medicine at Columbia University Irving Medical Center and director of the...
Videos | Antiplatelet and Anticoagulation Therapies | October 08, 2019
American Heart Association President Robert Harrington, M.D., explains the reasons for shorter duration dual-...
Three-Month DAPT Post-PCI Demonstrates Low Adverse Event Rate in High-Bleeding Risk Patients
News | Antiplatelet and Anticoagulation Therapies | September 30, 2019
Data from the EVOLVE Short DAPT study found that shortened three-month dual antiplatelet therapy (DAPT) did not...
Brilinta Monotherapy Reduces Clinically Relevant Bleeding Risk Post-PCI in High-Risk Patients
News | Antiplatelet and Anticoagulation Therapies | September 26, 2019
New data from the Phase IV independent TWILIGHT trial showed Brilinta (ticagrelor) monotherapy reduced the risk of BARC...